Evidence map›Paper›PMID 35406613›Full record

ArticleCancers2022

Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires.

Corinna Grunert, Gerald Willimsky, Caroline Anna Peuker, Simone Rhein, Leo Hansmann, Thomas Blankenstein, Eric Blanc, Dieter Beule, Ulrich Keller, Antonio Pezzutto and 1 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Corinna GrunertDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0001-8376-8629
Gerald WillimskyInstitute of Immunology, Campus Buch, Charité-Universitätsmedizin Berlin, 13092 Berlin, Germany.ORCID 0000-0002-9693-948X
Caroline Anna PeukerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-0957-2166
Simone RheinMax Delbrück Center for Molecular Medicine in the Helmholtz Association, 13092 Berlin, Germany.ORCID 0000-0002-9445-2352
Leo HansmannGerman Cancer Consortium (DKTK), Partner Site Berlin, CCCC (Campus Mitte), 10117 Berlin, Germany.ORCID 0000-0003-3790-0128
Thomas BlankensteinMax Delbrück Center for Molecular Medicine in the Helmholtz Association, 13092 Berlin, Germany.
Eric BlancCore Unit Bioinformatics, Berlin Institute of Health at Charité, 10117 Berlin, Germany.
Dieter BeuleCore Unit Bioinformatics, Berlin Institute of Health at Charité, 10117 Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-8485-1958
Antonio PezzuttoDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Antonia BusseDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-3470-6947

Funding

Berliner Krebsgesellschaft GRFF201821Deutsche Krebshilfe e.V. 70113355
6 · The paper itself

Abstract

(1) Background: Mutation-specific T cell receptor (TCR)-based adoptive T cell therapy represents a truly tumor-specific immunotherapeutic strategy. However, isolating neoepitope-specific TCRs remains a challenge. (2) Methods: We investigated, side by side, different TCR repertoires-patients' peripheral lymphocytes (PBLs) and tumor-infiltrating lymphocytes (TILs), PBLs of healthy donors, and a humanized mouse model-to isolate neoepitope-specific TCRs against eight neoepitope candidates from a colon cancer and an ovarian cancer patient. Neoepitope candidates were used to stimulate T cells from different repertoires in vitro to generate neoepitope-specific T cells and isolate the specific TCRs. (3) Results: We isolated six TCRs from healthy donors, directed against four neoepitope candidates and one TCR from the murine T cell repertoire. Endogenous processing of one neoepitope, for which we isolated one TCR from both human and mouse-derived repertoires, could be shown. No neoepitope-specific TCR could be generated from the patients' own repertoire. (4) Conclusion: Our data indicate that successful isolation of neoepitope-specific TCRs depends on various factors such as the heathy donor's TCR repertoire or the presence of a tumor microenvironment allowing neoepitope-specific immune responses of the host. We show the advantage and feasibility of using healthy donor repertoires and humanized mouse TCR repertoires to generate mutation-specific TCRs with different specificities, especially in a setting when the availability of patient material is limited.

Indexed as

antigen-specific T cellneoantigensT cell receptor repertoireT cell receptor (TCR) therapytumor-specific TCR

Identifiers

PMID35406613
PMCPMC8998067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.